Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

Ads

You May Also Like

Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update

SEATTLE, May 09, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, ...